Literature DB >> 19358775

Newer antiretroviral agents and how to use them.

Holly H Kim1, Eric S Daar.   

Abstract

Several relatively new antiretroviral drugs have been approved or are under investigation. These include nucleoside and nonnucleoside reverse transcriptase inhibitors, protease and integrase strand transfer inhibitors, CCR5 antagonists, and an entirely new class of maturation inhibitors. Although most of these drugs were developed for patients with drug-resistant HIV-1, some have demonstrated a potential role for those starting treatment for the first time. This review incorporates data from the most recent treatment guidelines, peer-reviewed publications, and recent presentations at research meetings about some of these relatively new and emerging antiretroviral agents and offers strategies for incorporating them into clinical practice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19358775     DOI: 10.1007/s11904-009-0009-9

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  21 in total

1.  Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection.

Authors:  Graeme J Moyle; Adrian Wildfire; Sundhiya Mandalia; Howard Mayer; James Goodrich; Jeannette Whitcomb; Brian G Gazzard
Journal:  J Infect Dis       Date:  2005-02-11       Impact factor: 5.226

2.  Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.

Authors:  Charles B Hicks; Pedro Cahn; David A Cooper; Sharon L Walmsley; Christine Katlama; Bonaventura Clotet; Adriano Lazzarin; Margaret A Johnson; Dietmar Neubacher; Douglas Mayers; Hernan Valdez
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

3.  Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis.

Authors:  Jing Lu; Steven G Deeks; Rebecca Hoh; George Beatty; Benjamin A Kuritzkes; Jeffrey N Martin; Daniel R Kuritzkes
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

4.  Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

Authors:  Scott M Hammer; Joseph J Eron; Peter Reiss; Robert T Schooley; Melanie A Thompson; Sharon Walmsley; Pedro Cahn; Margaret A Fischl; Jose M Gatell; Martin S Hirsch; Donna M Jacobsen; Julio S G Montaner; Douglas D Richman; Patrick G Yeni; Paul A Volberding
Journal:  JAMA       Date:  2008-08-06       Impact factor: 56.272

5.  Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.

Authors:  Raphael J Landovitz; Jonathan B Angel; Christian Hoffmann; Heinz Horst; Milos Opravil; Jianmin Long; Wayne Greaves; Gerd Fätkenheuer
Journal:  J Infect Dis       Date:  2008-10-15       Impact factor: 5.226

6.  Maraviroc for previously treated patients with R5 HIV-1 infection.

Authors:  Roy M Gulick; Jacob Lalezari; James Goodrich; Nathan Clumeck; Edwin DeJesus; Andrzej Horban; Jeffrey Nadler; Bonaventura Clotet; Anders Karlsson; Michael Wohlfeiler; John B Montana; Mary McHale; John Sullivan; Caroline Ridgway; Steve Felstead; Michael W Dunne; Elna van der Ryst; Howard Mayer
Journal:  N Engl J Med       Date:  2008-10-02       Impact factor: 91.245

7.  Baseline HIV type 1 coreceptor tropism predicts disease progression.

Authors:  Eric S Daar; Karen L Kesler; Christos J Petropoulos; Wei Huang; Michael Bates; Alice E Lail; Eoin P Coakley; Edward D Gomperts; Sharyne M Donfield
Journal:  Clin Infect Dis       Date:  2007-07-20       Impact factor: 9.079

8.  Raltegravir with optimized background therapy for resistant HIV-1 infection.

Authors:  Roy T Steigbigel; David A Cooper; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey L Lennox; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Bach-Yen Nguyen; Hedy Teppler
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

Authors:  David A Cooper; Roy T Steigbigel; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey L Lennox; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Hedy Teppler; Bach-Yen Nguyen
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

10.  Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

Authors:  Bonaventura Clotet; Nicholas Bellos; Jean-Michel Molina; David Cooper; Jean-Christophe Goffard; Adriano Lazzarin; Andrej Wöhrmann; Christine Katlama; Timothy Wilkin; Richard Haubrich; Calvin Cohen; Charles Farthing; Dushyantha Jayaweera; Martin Markowitz; Peter Ruane; Sabrina Spinosa-Guzman; Eric Lefebvre
Journal:  Lancet       Date:  2007-04-07       Impact factor: 79.321

View more
  1 in total

1.  HIV protease inhibitors, indinavir or nelfinavir, augment antimalarial action of artemisinin in vitro.

Authors:  Lokesh C Mishra; Amit Bhattacharya; Manish Sharma; Virendra K Bhasin
Journal:  Am J Trop Med Hyg       Date:  2010-01       Impact factor: 2.345

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.